Abstract

Because of improvements in the treatment of patients with metastatic breast cancer, the development of brain metastases (BM) has become a major limitation of life expectancy and quality of life for many breast cancer patients. The improvement of management strategies for BM is thus an important clinical challenge, especially among high-risk patients such as human epidermal growth factor receptor 2-positive and triple-negative patients. However, the formation of BM as a multistep process is thus far poorly understood. To grow in the brain, single tumor cells must pass through the tight blood–brain barrier (BBB). The BBB represents an obstacle for circulating tumor cells entering the brain, but it also plays a protective role against immune cell and toxic agents once metastatic cells have colonized the cerebral compartment. Furthermore, animal studies have shown that, after passing the BBB, the tumor cells not only require close contact with endothelial cells but also interact closely with many different brain residential cells. Thus, in addition to a genetic predisposition of the tumor cells, cellular adaptation processes within the new microenvironment may also determine the ability of a tumor cell to metastasize. In this review, we summarize the biology of breast cancer that has spread into the brain and discuss the implications for current and potential future treatment strategies.

Highlights

  • Because of improvements in the treatment of patients with metastatic breast cancer, long-term survival can be achieved

  • AMedian value and range from seven different studies reported by [85, 86] bSummarized data from the studies reported in [11, 12, 14] Human epidermal growth factor receptor (HER) human epidermal growth factor receptor, TNBC triple-negative breast cancer poorly differentiated tumors, hormone receptor-negative status, and four or more metastatic lymph nodes have been associated with increased brain metastases (BM) risk [1]

  • In HER2-positive breast cancer patients who progressed after wholebrain radiation therapy (WBRT), lapatinib monotherapy showed minor activity as a single agent [24]

Read more

Summary

Introduction

Because of improvements in the treatment of patients with metastatic breast cancer, long-term survival can be achieved. 15–30 % of patients with metastatic breast cancer will develop brain metastases (BM) during the course of the disease [1]. Lung and breast cancer BM are more commonly diagnosed than primary brain tumors.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.